Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: An open-label single-arm study

Journal of the Formosan Medical Association

Volumn 112, Issue 9, 2013, Pages 518-526

  Chang, Gee Chen ^a,b   Tsai, Chun Ming ^c   Hsia, Te Chun ^d,e   Yang, Chih Hsin ^f,g   Abdulnabi, Radhi ^h   Blair, Julie M ⁱ   Linn, Carlos ^j  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g Department of Oncology ^*  (Taiwan)

^h i3 Statprobe   (United States)

ⁱ ELI LILLY AUSTRALIA PTY LTD   (Australia)

^j Emerging Markets Business Unit   (Taiwan)

more..

Author keywords

Carcinoma; Chemotherapy; Clinical trial; Nonsmall cell lung cancer; Pemetrexed

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; FOLIC ACID; GEMCITABINE; PACLITAXEL; PEMETREXED;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ADVANCED NON SMALL CELL LUNG CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; LEUKOCYTE COUNT; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 4 CLINICAL TRIAL; SIDE EFFECT; TAIWAN; THROMBOCYTE; TREATMENT RESPONSE;

CARCINOMA; CHEMOTHERAPY; CLINICAL TRIAL; NONSMALL CELL LUNG CANCER; PEMETREXED;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 84884700353     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2012.02.030     Document Type: Article

References (24)

1. 2008 Taiwan Public Health Report 2009, Department of Health R.O.C. (Taiwan), Department of Health, Taiwan, R.O.C, Taipei.
2. Marugame T, Matsuda T. Comparison of time trends in lung cancer incidence (1973-2002) in Asia. In: Cancer Incidence in Five Continents Vols IV-IX. Jpn J Clin Oncol 2009;39:133-135.
3. Fathi A.T., Brahmer J.R. Chemotherapy for advanced stage non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2008, 20:210-216.
4. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
5. de Marinis F., Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 2008, 13:14-20.
6. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354-2362.
7. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
8. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
9. Cohen M.H., Johnson J.R., Wang Y.C., Sridhara R., Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005, 10:363-368.
10. Cohen M.H., Justice R., Pazdur R. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist 2009, 14:930-935.
11. Bearz A., Garassino I., Cavina R., Favaretto A., Boccalon M., Talamini R., et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 2008, 60:240-245.
12. Cullen M.H., Zatloukal P., Sörenson S., Novello S., Fischer J.R., Joy A.A., et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008, 19:939-945.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
14. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-656.
15. Introductory Guide MedDRA Version 11.0, MSSO-DI-6003-11.0.1. ; March 2008. http://www.meddra.org/sites/default/files/guidance/file/intguide_11_0_english.pdf.
16. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). ; August 9, 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
18. Ohe Y., Ichinose Y., Nakagawa K., Tamura T., Kubota K., Yamamoto N., et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008, 14:4206-4212.
19. Nakagawa K., Kudoh S., Matsui K., Negoro S., Yamamoto N., Latz J.E., et al. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 2006, 95:677-682.
20. Marsh S., Collie-Duguid E.S., Li T., Liu X., McLeod H.L. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999, 58:310-312.
21. Goekkurt E., Al-Batran S.E., Mogck U., Pauligk C., Hartmann J.T., Kramer M., et al. Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol 2009, 20:481-485.
22. Pullarkat S.T., Stoehlmacher J., Ghaderi V., Xiong Y.P., Ingles S.A., Sherrod A., et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001, 1:65-70.
23. Niyikiza C., Hanauske A.R., Rusthoven J.J., Calvert A.H., Allen R., Paoletti P., et al. Pemetrexed safety and dosing strategy. Semin Oncol 2002, 29:24-29.
24. Esteban E., Casillas M., Cassinello A. Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treat Rev 2009, 35:364-373.